Ramifications of Hurwitz theory, KP integrability and quantum curves von Alexandrov, A., Lewanski, D., Shadrin, S.

Volltext

Polynomiality of orbifold Hurwitz numbers, spectral curve, and a new proof of the Johnson–Pandharipande–Tseng formula von Dunin‐Barkowski, P., Lewanski, D., Popolitov, A., Shadrin, S.

Volltext

Harer–Zagier formula via Fock space von Lewański, D.

Volltext

Towards an orbifold generalization of Zvonkine's r-ELSV formula von Kramer, R., Lewanski, D., Popolitov, Aleksandr, Shadrin, S.

Volltext

TOWARDS AN ORBIFOLD GENERALIZATION OF ZVONKINE’S r-ELSV FORMULA von KRAMER, R., LEWANSKI, D., POPOLITOV, A., SHADRIN, S.

Volltext

Towards an orbifold generalization of Zvonkine’s -ELSV formula von Kramer, R., Lewanski, D., Popolitov, A., Shadrin, S.

Volltext

Towards an orbifold generalization of Zvonkine’s r r -ELSV formula von Kramer, R., Lewanski, D., Popolitov, A., Shadrin, S.

Volltext

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial von Fehrenbacher, Louis, Dr, Spira, Alexander, MD, Ballinger, Marcus, PhD, Kowanetz, Marcin, PhD, Vansteenkiste, Johan, Prof, Mazieres, Julien, Prof, Park, Keunchil, Prof, Smith, David, MD, Artal-Cortes, Angel, MD, Lewanski, Conrad, MD, Braiteh, Fadi, MD, Waterkamp, Daniel, MD, He, Pei, PhD, Zou, Wei, PhD, Chen, Daniel S, MD, Yi, Jing, PhD, Sandler, Alan, MD, Rittmeyer, Achim, MD

Volltext

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL... von Garon, Edward B, Dr, Ciuleanu, Tudor-Eliade, Prof, Arrieta, Oscar, MD, Prabhash, Kumar, Prof, Syrigos, Konstantinos N, Prof, Goksel, Tuncay, Prof, Park, Keunchil, Prof, Gorbunova, Vera, MD, Kowalyszyn, Ruben Dario, MD, Pikiel, Joanna, MD, Czyzewicz, Grzegorz, MD, Orlov, Sergey V, Prof, Lewanski, Conrad R, MD, Thomas, Michael, Prof, Bidoli, Paolo, MD, Dakhil, Shaker, MD, Gans, Steven, MD, Kim, Joo-Hang, Prof, Grigorescu, Alexandru, Prof, Karaseva, Nina, MD, Reck, Martin, MD, Cappuzzo, Federico, MD, Alexandris, Ekaterine, MS, Sashegyi, Andreas, PhD, Yurasov, Sergey, MD, Pérol, Maurice, MD

Volltext

Ramifications of Hurwitz theory, KP integrability and quantum curves von Alexandrov, A, Lewanski, D, Shadrin, S

Volltext

Masur-Veech volumes and intersection theory: the principal strata of quadratic differentials von Chen, D, Möller, M, Sauvaget, A, with an appendix by G Borot, Giacchetto, A, Lewanski, D

Volltext

Reference Genome Choice and Filtering Thresholds Jointly Influence Phylogenomic Analyses von Rick, Jessica A, Brock, Chad D, Lewanski, Alexander L, Golcher-Benavides, Jimena, Wagner, Catherine E

Volltext

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial von Lee, Siow Ming, Prof, Khan, Iftekhar, MSc, Upadhyay, Sunil, MD, Lewanski, Conrad, FRCP, Falk, Stephen, MD, Skailes, Geraldine, FRCR, Marshall, Ernie, MD, Woll, Penella J, Prof, Hatton, Matthew, FRCR, Lal, Rohit, MRCP, Jones, Richard, FRCR, Toy, Elizabeth, FRCR, Chao, David, DPhil, Middleton, Gary, MD, Bulley, Sue, SRN, Ngai, Yenting, BSc, Rudd, Robin, MD, Hackshaw, Allan, Prof, Boshoff, Chris, Prof

Volltext

Phase I-II study of pegylated liposomal cisplatin (SPI-077 TM) in patients with inoperable head and neck cancer von Harrington, K. J., Lewanski, C. R., Northcote, A. D., Whittaker, J., Wellbank, H., Vile, R. G., Peters, A. M., Stewart, J. S. W.

Volltext

122 To determine ideal gross tumour volumes and PTV expansion using four-dimensional computed tomography for the treatment of lung cancer von Goyal, N, Ingle, M, Bhuva, N, Power, D, Lewanski, C

Volltext

Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group ra... von Ferry, David, Billingham, Lucinda, Jarrett, Hugh, Dunlop, David, Woll, Penella J., Nicolson, Marianne, Shah, Riyaz, Thompson, Joyce, Spicer, James, Muthukumar, D., Skailes, Geraldine, Leonard, Pauline, Chetiyawardana, A.D., Wells, Paula, Lewanski, Conrad, Crosse, Barbara, Hill, Michelle, Gaunt, Piers, O'Byrne, Kenneth

Volltext

14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (P... von Vansteenkiste, J, Fehrenbacher, L, Spira, A.I, Mazieres, J, Park, K, Smith, D, Artal-Cortes, A, Lewanski, C, Braiteh, F, Yi, J, He, P, Kowanetz, M, Waterkamp, D, Ballinger, M, Chen, D.S, Sandler, A, Rittmeyer, A

Volltext

P1.01-93 Quality of Life in Patients with Advanced NSCLC Treated in Second- or Third-Line with Nab-Paclitaxel + Durvalumab: ABOUND.2L von Talbot, D., Govindan, R., Cobo, M., Ponce Aix, S., Postmus, P.E., Lewanski, C., Bennouna, J., Fischer, J., Juan-Vidal, O., Stewart, D., Ardizzoni, A., Bhore, R., Wolfsteiner, M., Reck, M., Morgensztern, D., Ong, T.J.

Volltext

P1.01-70 Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel + Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+) von Morgensztern, D., Govindan, R., Cobo, M., Ponce Aix, S., Postmus, P.E., Lewanski, C., Bennouna, J., Fischer, J., Juan-Vidal, O., Stewart, D., Ardizzoni, A., Bhore, R., Wolfsteiner, M., Reck, M., Talbot, D., Ong, T.J.

Volltext

ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC) von Morgensztern, D., Ong, T.J., Dols, M. Cobo, Aix, S. Ponce, Postmus, P.E., Lewanski, C., Bennouna, J., Fischer, J.R., Vidal, O.J., Stewart, D.J., Fasola, G., Ardizoni, A., Weaver, J., Wolfsteiner, M., Talbot, D., Govindan, R.

Volltext